A Study to Assess the Pharmacokinetics of Ramucirumab (IMC-1121B) in Combination With FOLFIRI

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

29 participants

Study Classification

INTERVENTIONAL

Study Start Date

2012-10-31

Study Completion Date

2018-02-28

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to assess the effect of concomitant ramucirumab (IMC-1121B) on the pharmacokinetics of irinotecan and its metabolite SN-38 when coadministered with folinic acid and 5-fluorouracil, in participants with advanced malignant solid tumors resistant to standard therapy or for which no standard therapy is available.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Study of Irinotecan, Levofolinate, and 5-Fluorouracil (FOLFIRI) Plus Ramucirumab (IMC-1121B)

NCT01286818

Colorectal Carcinoma

COMPLETED PHASE1

A Study in Second Line Metastatic Colorectal Cancer

NCT01183780

Colorectal Cancer

COMPLETED PHASE3

Panitumumab Plus FOLFIRI in First-line Treatment of Metastatic Colorectal Cancer

NCT00508404

Metastatic Colorectal Cancer

COMPLETED PHASE2

Comparison of Treatment Effect of Chemotherapy With Panitumumab to Chemotherapy Alone

NCT00339183

Metastatic Colorectal Cancer

COMPLETED PHASE3

Ramucirumab and Paclitaxel or FOLFIRI in Advanced Small Bowel Cancers

NCT04205968

Metastatic Small Intestinal Adenocarcinoma Stage III Small Intestinal Adenocarcinoma AJCC v8 Stage IIIA Small Intestinal Adenocarcinoma AJCC v8 +2 more

RECRUITING PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Solid Tumors

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

ramucirumab (IMC-1121B) and FOLFIRI

Treatment is sequential, Ramucirumab (IMC-1121B) will be administered before FOLFIRI ((Irinotecan + Folinic acid + 5-Fluorouracil). FOLFIRI will be administered each cycle and Ramucirumab (IMC-1121B) will be administered beginning from Cycle 2 (2-week cycle).

Group Type EXPERIMENTAL

Ramucirumab (IMC-1121B)

Intervention Type BIOLOGICAL

Ramucirumab (IMC-1121B) 8 milligrams per kilogram (mg/kg), administered as an intravenous (IV) infusion on Day 1 of each 2-week cycle (except Cycle 1)

Irinotecan

Intervention Type DRUG

180 milligrams per square meter (mg/m²) administered IV on Day 1 of each cycle

Folinic acid

Intervention Type DRUG

400 mg/m² administered IV on Day 1 of each cycle

5-Fluorouracil

Intervention Type DRUG

400 mg/m² bolus over 2 to 4 minutes administered IV on Day 1 of each cycle, followed by 2400 mg/m² administered IV over 46 to 48 hours on Days 1 and 2 of each cycle

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Ramucirumab (IMC-1121B)

Ramucirumab (IMC-1121B) 8 milligrams per kilogram (mg/kg), administered as an intravenous (IV) infusion on Day 1 of each 2-week cycle (except Cycle 1)

Intervention Type BIOLOGICAL

Irinotecan

180 milligrams per square meter (mg/m²) administered IV on Day 1 of each cycle

Intervention Type DRUG

Folinic acid

400 mg/m² administered IV on Day 1 of each cycle

Intervention Type DRUG

5-Fluorouracil

400 mg/m² bolus over 2 to 4 minutes administered IV on Day 1 of each cycle, followed by 2400 mg/m² administered IV over 46 to 48 hours on Days 1 and 2 of each cycle

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

IMC-1121B LY3009806

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Has histologic or cytologic documentation of a malignant solid tumor
* Has an advanced solid tumor that is resistant to standard therapy or for which no standard therapy is available
* Has resolution to Grade ≤1, per the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0 (NCI-CTCAE v. 4.0), of all clinically significant toxic effects of prior chemotherapy, surgery, radiotherapy, or hormonal therapy
* Has an Eastern Cooperative Oncology Group (ECOG) performance status of 0-2
* Has adequate hematologic, coagulation, and hepatic function
* Has serum creatinine ≤ 1.5 x upper limit of normal (ULN)
* Urinary protein is \<2+ on dipstick or routine urinalysis (UA) at study entry
* Women with childbearing potential must have a negative serum or urine pregnancy test
* Eligible participants of reproductive potential (both sexes) agree to use adequate method of contraception during the study period and for 12 weeks after the last dose of study medication

Exclusion Criteria

* Has received a therapeutic monoclonal antibody within the last 42 days
* Has received cytotoxic chemotherapy within the last 21 days
* Has received radiotherapy within the last 14 days
* Are currently enrolled in, or discontinued within the last 14 days from, a clinical trial involving an investigational product or non-approved use of a drug or device, or concurrently enrolled in any other type of medical research judged not to be scientifically or medically compatible with this study
* Has a history of deep vein thrombosis, pulmonary embolism, or any other significant thromboembolism during the last 3 months
* Has an uncontrolled illness, including, but not limited to uncontrolled hypertension, symptomatic congestive heart failure, unstable angina pectoris, symptomatic or poorly controlled cardiac arrhythmia, psychiatric illness/social situations, or any other serious uncontrolled medical disorders
* Has experienced any arterial thromboembolic event within the last 6 months
* Has known leptomeningeal disease or brain metastases or uncontrolled spinal cord compression
* Has an ongoing or active infection requiring parenteral antibiotic, antifungal, or antiviral therapy
* Has known human immunodeficiency virus infection or acquired immunodeficiency syndrome-related illness
* Has received a prior organ or transplantation
* Has undergone major surgery within the last 28 days
* Has had a serious nonhealing wound, ulcer, or bone fracture within the last 28 days
* Has an elective or planned major surgery to be performed during the course of the trial
* Has a bowel obstruction, history or presence of inflammatory enteropathy or extensive intestinal resection, Crohn's disease, ulcerative colitis, or chronic diarrhea
* Has experienced a Grade 3 or higher bleeding event within the last 3 months
* Has a known history or clinical evidence of Gilbert's Syndrome, or is known to have any of the following genotypes: uridine diphosphate glucuronosyltransferase isoform 1A1 (UGT1A1)\*6/\*6, UGT1A1\*28/\*28, or UGT1A1\*6/\*28
* Has received clinically relevant inhibitors or inducers of cytochrome P (CYP) 450 CYP3A4/5 or CYP2C9 and/or isoenzymes within the last 3 weeks
* Has cirrhosis at a level of Child-Pugh B (or worse), or cirrhosis and a history of hepatic encephalopathy, or ascites resulting from cirrhosis and requiring ongoing treatment with diuretics and/or paracentesis

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No